Show simple item record

dc.rights.licenseAttribution-NonCommercial 4.0 International (CC BY-NC 4.0)
dc.creatorO'Bryant, Sid E.
dc.creatorZhang, Fan
dc.creatorSilverman, Wayne
dc.creatorLee, Joseph H.
dc.creatorKrinsky-McHale, Sharon J.
dc.creatorPang, Deborah
dc.creatorHall, James R.
dc.creatorSchupf, Nicole
dc.date.accessioned2022-07-07T13:54:27Z
dc.date.available2022-07-07T13:54:27Z
dc.date.issued2020-05-21
dc.identifier.citationO'Bryant, S. E., Zhang, F., Silverman, W., Lee, J. H., Krinsky-McHale, S. J., Pang, D., Hall, J., & Schupf, N. (2020). Proteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome. Alzheimer's & dementia (Amsterdam, Netherlands), 12(1), e12033. https://doi.org/10.1002/dad2.12033
dc.identifier.issn2352-8729
dc.identifier.urihttps://hdl.handle.net/20.500.12503/31540
dc.description.abstractIntroduction: We sought to determine if proteomic profiles could predict risk for incident mild cognitive impairment (MCI) and Alzheimer's disease (AD) among adults with Down syndrome (DS). Methods: In a cohort of 398 adults with DS, a total of n = 186 participants were determined to be non-demented and without MCI or AD at baseline and throughout follow-up; n = 103 had incident MCI and n = 81 had incident AD. Proteomics were conducted on banked plasma samples from a previously generated algorithm. Results: The proteomic profile was highly accurate in predicting incident MCI (area under the curve [AUC] = 0.92) and incident AD (AUC = 0.88). For MCI risk, the support vector machine (SVM)-based high/low cut-point yielded an adjusted hazard ratio (HR) = 6.46 (P < .001). For AD risk, the SVM-based high/low cut-point score yielded an adjusted HR = 8.4 (P < .001). Discussion: The current results provide support for our blood-based proteomic profile for predicting risk for MCI and AD among adults with DS.
dc.description.sponsorshipThis work was supported by the National Institutes of Health grants: P01 HD035897, U54 HD079123, U01 AG051412 and R01 AG014673, and by grant IIRG-08-90655 from the Alzheimer's Association as well as by funds from the New York State Office for People with Developmental Disabilities. This work was also supported by the National Institute on Aging grant R01 AG058537.
dc.publisherWiley Periodicals, Inc.
dc.relation.urihttps://doi.org/10.1002/dad2.12033
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceAlzheimer's & Dementia: Diagnosis Assessment & Disease Monitoring
dc.subjectmild cognitive impairment
dc.subjectproteomic
dc.subject.meshDown Syndrome
dc.subject.meshCognitive Dysfunction
dc.subject.meshDementia
dc.subject.meshPlasma
dc.titleProteomic profiles of incident mild cognitive impairment and Alzheimer's disease among adults with Down syndrome
dc.typeArticle
dc.rights.holderCopyright © 2020 The Authors.
dc.type.materialtext
dc.creator.orcid0000-0003-0582-5266 (O'Bryant, Sid E.)
dc.identifier.volume12
dc.identifier.issue1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)